Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation

Alcohol withdrawal syndrome is a significant clinical challenge that can range from uncomfortable to life-threatening, and safer treatment options are continually sought. This study by Kolik, Nadorova, and Kozlovskaya evaluated Selank's efficacy during alcohol withdrawal in rats that had developed stable alcoholic motivation.

The researchers established a model of stable alcohol dependence in rats and then assessed Selank's effects during the withdrawal period. Behavioral measures of withdrawal severity, anxiety, and distress were monitored to determine whether the peptide anxiolytic could meaningfully alleviate withdrawal symptoms.

The results demonstrated that Selank effectively alleviates alcohol withdrawal symptoms in animals with established alcohol dependence. The peptide reduced anxiety and distress during the withdrawal period, providing relief without the sedation or additional dependence risk associated with conventional treatments like benzodiazepines.

This finding supports Selank's therapeutic potential as a peptide-based anxiolytic specifically suited for substance use recovery contexts. For individuals navigating the difficult process of alcohol withdrawal, having access to an effective anti-anxiety treatment that does not carry its own addiction risk represents a meaningful advancement in supportive care.